Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФППОВ ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ
Список исп. литературыСкрыть список 1. Аведисова А.С. Современная классификация антидепрессантов: возможности повышения эффективности и безопасности. Психиатр. и психофармакотер. 2000; 2. 2. Краснов В.Н. Современные подходы к терапии депрессий. Рус. мед. журн. 2002; (12–13): 553. 3. Мосолов С.Н. Клиническое применение современных антидепрессантов. СПб., 1995. 4. Смулевич А.Б. Депрессия и коморбидные расстройства. М., 1997. 5. Смулевич А.Б. Депрессия в общей медицине. М., 2001. 6. Смулевич А.Б. Клинико-фармакологические эффекты антидепрессантов. Психиатр. и психофармакотер. (Прил.). 2003; 1: 3–6. 7. Смулевич А.Б. Депрессии при соматических и психических заболеваниях. М., 2003. 8. Смулевич А.Б. Психокардиология. М., 2005. 9. Смулевич А.Б. Психические расстройства в клинической практике. М., 2011. 10. Яковлева О.Б. Вопросы эффективности и безопасности антидепрессантов при лечении депрессий позднего возраста. Клин. психофармакология. 1998; 1 (4). 11. American Psychiatric Association – APA. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington (VA). Am Psychiat Assoc 2010. 12. Brambilla P, Cipriani A, Hotopf M, Barbui C. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiat 2005; 38 (2): 69–77. 13. Chua HC, Chan LL, Chee KS et al. Ministry of health clinical practice guidelines: depression. Singapore Med J 2012; 53 (2): 137–43. 14. Cipriani A, Brambilla P, Furukawa TA et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Rev 2005; 4. CD004185. DOI: 10.1002/14651858.CD004185.pub2 15. Cipriani A, La Ferla T, Furukawa TA et al. Sertraline vs other antidepressive agents for depression. Cochrane Database Syst Rev 2010; 14 (4): CD006117. 16. Dannon PN, Lowengrub K, Gonopolski Y, Kotler M. Current and emerging somatic treatment strategies in psychotic major depression. Expert Rev 2006; 6: 73–80. 17. Eberhard-Gran M, Eskild A, Opjordsmoen S. Use of psychotropic medications in treating mood disorders during lactation: practical recommendations. CNS Drugs 2006; 20: 187–98. 18. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiat 2001; 62: 869–77. 19. Fournier JC, DeRubeis RJ, Hollon SD et al. Antidepressant drug effects and depression severity: a patientlevel meta-analysis. JAMA 2010; 303: 47–53. 20. Gartlehner G, Hansen RA, Morgan LC et al. Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. Rockville (MD). Agency for Healthcare Research and Quality (US) 2011; 12-EHC012-EF. 21. Grigoriadis S, Konarski JZ, Kennedy SH et al. Sex differences in antidepressant response in a Canadian primary care sample. J Clin Psychopharmacol 2007; 27: 95–8. 22. Kato M, Fukuda T, Serretti A et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patientswithmajor depressive disorder. Prog Neuropsychopharmacol Biol Psychiat 2008; 32: 398–404. 23. Kennedy SH, Lam RW, Parikh SV et al. Canadian network for mood and anxiety treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Dis 2009; 117 (Suppl. 1): s1–2. 24. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002; 22: 40–5. 25. Khan A, Brodhead AE, Schwartz KA et al. Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol 2005; 25: 318–24. 26. Kielholz P. Psychiatrische Pharmakotherapie in Klinik und Praxis. Bern, Stuttgart 1965. 27. Kirsch I, Deacon BJ, Huedo-Medina TB et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5: e45. 28. Kornstein SG, Wohlreich MM, Mallinckrodt CH et al. Duloxetine efficacy for major depressive disorder in male vs female patients: data from 7 randomized, double-blind, placebo-controlled trials. J Clin Psychiat 2006; 67: 761–70. 29. McMahon FJ, Buervenich S, Charney D et al. Variation in the gene encoding the serotonin 2A-receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804–14. 30. Modell JG, Rosenthal NE, Harriett AE et al. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiat 2005; 58: 658–67. 31. Mulder RT, Watkins WG, Joyce PR, Luty SE. Age may affect response to antidepressants with serotonergic and noradrenergic actions. J Affect Dis 2003; 76: 143–9. 32. Papakostas GI, Kornstein SG, Clayton AH et al. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Int Clin Psychopharmacol 2007; 22: 226–9. 33. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within vs across-class switches. Biol Psychiat 2008; 63 (7): 699–704. 34. Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a 1st selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiat 2006; 67 (12): 1836–55. 35. Rush AJ, Trivedi MH, Wisniewski SR et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354 (12): 1231–42. 36. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiat 2007; 12: 247–57. 37. Weissman AM, Levy BT, Hartz AJ et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiat 2004; 161: 1066–78. 38. Wijkstra J, Lijmer J, Balk FJ et al. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiat 2006; 188: 410–5. 39. Wisner KL, Perel JM, Peindl KS et al. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiat 2001; 62: 82–6. 40. Wisner KL, Perel JM, Peindl KS et al. Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiat 2004; 161: 1290–2. 41. Young EA, Kornstein SG, Marcus SM et al. Sex differences in response to citalopram: a STAR*D report. J Psychiat 2008.